Michael Peel, a medicinal chemist with an expertise in cyclophilin inhibition, has joined UK-based Cypralis Ltd as chief scientific officer. He previously directed drug discovery at Scynexis Inc where he led work on a new antifungal treatment as well as researched cyclophilin inhibition for application in virology, ophthalmology and immunology. Early in his career he played a key role in GlaxoSmithKline’s research into kinase inhibition. Dr Peel earned his PhD at Sheffield University in the UK.
Cypralis announced the appointment on 2 March 2016.
Copyright 2016 Evernow Publishing Ltd